News | April 28, 2023
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
The business and product range of Ipca and that of Unichem complements each others business and product range
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Subscribe To Our Newsletter & Stay Updated
